## Does Beta-Band EEG Reliably Track Motor Decline in ALS?

A dual-site international study enrolling 199 participants — 99 with [amyotrophic lateral sclerosis (ALS)](https://bciintel.com/glossary/als) and 100 matched controls — finds that beta-band event-related desynchronization (ERD) and post-movement event-related synchronization (ERS) partially replicate as EEG markers of motor cortex dysfunction, but with a critical caveat: the biomarker held in the Irish cohort and failed to reach significance in the Dutch cohort. That split result is the most important finding in this paper, and it demands careful interpretation before anyone positions these oscillatory signatures as a clinical endpoint.

The study, posted to arXiv on August 28, 2026 (arXiv:2608.27003), used 128-channel [electroencephalography (EEG)](https://bciintel.com/glossary/eeg) during a randomized sustained attention to response task (SART) across Dutch (ALS n=63; controls n=64) and Irish (ALS n=36; controls n=36) sites. Across both ALS groups, people with ALS showed reduced Go and total accuracy compared to controls (p < 0.002), and the Irish cohort additionally showed slower Go response times (p=0.02). Greater beta ERS was associated with faster Go responses in both centers (p < 0.011), providing a cross-cohort functional anchor for the measure.

---

## What the SART Protocol Reveals About Cortical Motor Networks

The sustained attention to response task is a well-established inhibitory control paradigm, but its application to ALS-related [event-related potential (ERP)](https://bciintel.com/glossary/event-related-potential) and oscillatory profiling is relatively recent. In the healthy control groups at both sites, the SART produced a consistent oscillatory fingerprint: theta ERS and alpha- and beta-band ERD during stimulus processing, followed by rebound beta ERS across the frontoparietal axis. NoGo trials, which require active motor suppression, elicited greater theta ERS, stronger alpha ERD, and weaker beta ERS compared to Go trials — exactly the pattern one would expect from preserved inhibitory circuitry.

The ALS-specific deviation from this pattern is where the biomarker story gets complicated. Prior published work had identified reduced beta ERD and attenuated post-movement beta ERS in ALS patients during SART — interpreted as cortical motor network disorganization consistent with upper motor neuron involvement. This new dual-site study aimed to validate those findings with substantially larger samples and geographic replication. The Irish cohort replicated the prior result: reduced beta ERD and ERS versus controls. The Dutch cohort did not show these differences.

The authors attribute cohort divergence, at least in part, to differences in functional impairment between the two ALS groups. The Dutch and Irish cohorts differed significantly across multiple behavioral measures — NoGo accuracy, Go response time, and anticipation errors (all p=0.03). This is a plausible and methodologically honest explanation, but it also underscores the fundamental challenge for ALS biomarker development: disease heterogeneity may be too large for a single oscillatory signature to serve as a universal marker across populations with varying impairment profiles.

---

## Why Partial Replication Matters for BCI-Adjacent ALS Research

For the [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) field, this study sits at a critical juncture. Companies like [Synchron](https://bciintel.com/companies/synchron) are enrolling ALS patients in clinical trials using endovascular neural interfaces specifically because ALS causes progressive motor pathway degeneration. The ability to objectively track that degeneration — not just through clinical scales like ALSFRS-R, but through quantifiable neural biomarkers — would strengthen both trial design and the regulatory case for adaptive BCI systems that can adjust decoding parameters as disease progresses.

Beta-band dynamics are particularly relevant here. Beta ERD preceding voluntary movement and the subsequent beta rebound (ERS) are signatures of motor cortex engagement and disengagement. An ALS patient whose beta ERS is attenuated is, by this measure, showing cortical motor network dysfunction that may precede or parallel the clinical motor decline that makes BCI communication increasingly necessary. If EEG-based beta oscillation metrics could be validated as reliable surrogate markers, they could serve as objective enrollment criteria, disease progression endpoints, or triggers for BCI parameter adaptation in closed-loop systems.

This study advances that agenda — but doesn't complete it. The partial replication is a meaningful step, not a definitive validation. The behavioral finding that greater beta ERS correlates with faster Go responses in both cohorts (p < 0.011) is the strongest cross-site result and suggests the measure captures something real about motor network function. But a biomarker that replicates in one of two sites, with cohort differences that are incompletely characterized, is not yet ready for clinical trial endpoint adoption.

---

## Methodological Strengths and Limitations

**Strengths worth noting:**

- 128-channel EEG provides dense spatial sampling well beyond typical clinical EEG, enabling more precise frontoparietal source attribution
- Matched control groups (n=64 Dutch; n=36 Irish) reduce confounding from age-related oscillatory changes
- Use of complex Morlet wavelets for non-phase-locked activity quantification is methodologically appropriate for beta ERD/ERS extraction
- Randomized SART design reduces sequence effects
- The study is preregistered as a replication attempt, which carries higher evidential weight than a post-hoc reanalysis

**Limitations requiring scrutiny:**

- The Dutch cohort (n=63 ALS) is larger than the Irish (n=36 ALS), yet showed *fewer* EEG differences — size alone cannot explain the discrepancy, pointing to genuine population heterogeneity
- Functional impairment metrics differed between cohorts on multiple measures (p=0.03), but the paper does not fully characterize what clinical or demographic variables drove these differences
- EEG-based ERD/ERS cannot disambiguate upper versus lower motor neuron involvement, which varies substantially across ALS phenotypes
- The arXiv preprint has not undergone peer review at time of publication

---

## Implications for Clinical Translation Timeline

Reliable EEG biomarkers for ALS motor decline would compress clinical trial timelines by reducing sample sizes needed to detect disease progression — a persistent obstacle in ALS trials given the disease's variable trajectory and relatively small patient population. The current study's mixed replication result suggests that single-site EEG biomarker findings in ALS should not be assumed to generalize, and that future validation studies need to prospectively harmonize patient populations on functional impairment severity before pooling or comparing oscillatory metrics.

For BCI developers specifically, the implication is that beta oscillation profiles may eventually stratify ALS patients by cortical motor network integrity — potentially informing which patients are best candidates for motor imagery-based BCI control versus alternative paradigms that rely less on preserved beta dynamics.

This work was conducted across Dutch and Irish cohorts by a multi-institutional team including researchers affiliated with University Medical Center Utrecht and Beaumont Hospital Dublin, among others, based on the author affiliations listed.

*Note: These findings are from a preprint observational study. Results have not been peer-reviewed and should not be interpreted as clinical guidance.*

---

## Key Takeaways

- **199 participants** (99 ALS, 100 controls) across Dutch and Irish sites used 128-channel EEG during a randomized SART
- **Beta ERD and ERS changes replicated in the Irish cohort** but not the Dutch cohort, limiting immediate generalizability
- **Cross-cohort behavioral result**: greater beta ERS correlated with faster Go responses at both sites (p < 0.011), suggesting functional validity of the measure
- **ALS participants showed reduced accuracy** on Go and total trials at both sites (p < 0.002), confirming cognitive-motor involvement
- **Cohort heterogeneity in functional impairment** — not just sample size — appears to drive the replication gap
- EEG beta oscillation metrics are promising but not yet validated as universal ALS biomarkers for BCI trial endpoints or clinical use

---

## Frequently Asked Questions

**What are beta ERD and ERS in the context of ALS?**
Beta event-related desynchronization (ERD) is a decrease in beta-band (roughly 13–30 Hz) EEG power that occurs before and during voluntary movement, reflecting cortical motor network activation. Event-related synchronization (ERS) is the rebound increase in beta power after movement, reflecting motor network "idling." In ALS, both are reportedly attenuated, consistent with upper motor neuron degeneration disrupting normal frontoparietal motor circuitry.

**Why did the biomarker replicate in Ireland but not the Netherlands?**
The authors attribute the discrepancy, at least partly, to differences in functional impairment between the two ALS cohorts. The Dutch and Irish groups differed significantly on NoGo accuracy, Go response time, and anticipation errors (all p=0.03). A biomarker tied to motor network dysfunction may be more detectable in patients with greater functional impairment at time of testing.

**How does this research relate to BCI development for ALS patients?**
ALS is a primary target population for motor BCIs, including systems developed by companies like [Synchron](https://bciintel.com/companies/synchron) using endovascular approaches. Validated EEG biomarkers of motor cortex dysfunction could improve patient stratification, trial design, and adaptive BCI parameter tuning as disease progresses.

**Is the SART a standard ALS assessment tool?**
The sustained attention to response task is an established cognitive neuroscience paradigm for probing inhibitory control, but its use as an ALS biomarker assessment is research-stage only. It is not a standard clinical assessment tool in routine ALS care.

**What needs to happen before beta oscillation metrics can be used in clinical trials?**
Prospective harmonization of patient populations by functional impairment level, multi-site validation with pre-specified analysis plans, and ideally longitudinal data showing that beta ERD/ERS tracks disease progression over time — not just cross-sectional group differences — would be required before regulatory acceptance as a trial endpoint.